Understanding how claudin-2 affects calcium levels and kidney stones
Role of claudin-2 in Calcium Homeostasis and Kidney Stone Disease
This study is looking at how a protein called claudin-2 affects calcium levels in the body and could help us find new treatments for people who get kidney stones, especially those with high calcium in their urine.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Kansas Medical Center NIH-funded |
| Lab location | 1 site (Kansas City, United States) |
| Project ID | NIH-10690746 on NIH RePORTER |
What this research studies
This research investigates the role of claudin-2, a protein that helps regulate calcium absorption in the kidneys and intestines, in the development of kidney stones. By studying mice with altered claudin-2 levels, the researchers aim to understand how this protein influences calcium reabsorption and secretion. The findings could lead to new therapies for individuals suffering from kidney stones, particularly those with idiopathic hypercalciuria, a condition characterized by high calcium levels in urine. The research employs advanced techniques such as tubule micropuncture and genetic analysis to explore these mechanisms.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals with a history of kidney stones or those diagnosed with idiopathic hypercalciuria.
Not a fit: Patients who do not have kidney stones or related calcium absorption issues may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to novel treatments for kidney stone disease, improving the quality of life for affected patients.
How similar studies have performed: Other research has shown promising results in understanding calcium regulation and its link to kidney stones, suggesting that this approach could yield valuable insights.
Where this research is happening
Kansas City, United States
- University of Kansas Medical Center — Kansas City, United States (Active)
Researchers
- Principal investigator: Yu, Alan S — University of Kansas Medical Center
- Study coordinator: Yu, Alan S
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.